PMID- 31781662
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20220411
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2019
DP  - 2019
TI  - The Association between Genomic DNA Methylation and Diabetic Peripheral 
      Neuropathy in Patients with Type 2 Diabetes Mellitus.
PG  - 2494057
LID - 10.1155/2019/2494057 [doi]
LID - 2494057
AB  - AIM: DNA methylation is thought to be involved in regulating the expression of 
      key genes and inducing diabetic peripheral neuropathy (DPN). However, clinically, 
      the level of whole-genome DNA methylation and its relationship with DPN remains 
      unclear. METHODS: 186 patients with type 2 diabetes mellitus (T2DM) admitted to 
      the Second Affiliated Hospital of Soochow University since Jul. 2016 to Oct. 2017 
      were enrolled in the study, including 100 patients in the DPN group and 86 
      patients in the non-DPN group, diagnosed with Toronto Clinical Scoring System 
      (TCSS). Clinical and biochemical characteristics between the two groups were 
      compared, and the correlations with TCSS scores were analyzed. Furthermore, the 
      levels of genomic DNA methylation of leukocytes, measured with high-performance 
      liquid chromatography-tandem mass spectrometry (LC-MS/MS), were also analyzed 
      between the two groups. RESULTS: Age, duration, triglyceride (TG), total 
      cholesterol (TC), low-density lipoprotein (LDL-C), creatinine, uric acid (UA), 
      blood urea nitrogen (BUN), and C-reactive protein (CRP) were significantly higher 
      in the DPN group. Estimated glomerular filtration rate (eGFR) and the level of 
      genomic DNA methylation were much lower in the DPN group. Spearman correlation 
      analysis showed that TCSS was positively correlated with age, duration, UA, and 
      CRP and was negatively correlated with body mass index (BMI), eGFR, and the level 
      of genomic DNA methylation. Interestingly, multiple stepwise regression analysis 
      showed that only duration, genomic DNA methylation, and eGFR had impacts on TCSS. 
      The results also showed that the levels of genomic DNA methylation did not change 
      significantly whether or not there was renal injury. Another multiple stepwise 
      regression analysis showed that TCSS and BMI were the influencing factors of 
      genomic DNA methylation. Finally, we found that genomic DNA methylation levels 
      were decreased significantly in the DPN group compared with the non-DPN group 
      when the duration is >/=5 years or BMI >/= 25 kg/m(2). CONCLUSION: Low level of 
      genomic DNA methylation is a relative specific risk factor of diabetic peripheral 
      neuropathy in patients with type 2 diabetes.
CI  - Copyright (c) 2019 Hong-Hong Zhang et al.
FAU - Zhang, Hong-Hong
AU  - Zhang HH
AUID- ORCID: 0000-0002-6979-9020
AD  - Department of Endocrinology, The Second Affiliated Hospital, Soochow University, 
      Suzhou 215004, China.
FAU - Han, Xingfa
AU  - Han X
AD  - Department of Endocrinology, Suzhou Science and Technology Town Hospital, Nanjing 
      Medical University, Suzhou 215004, China.
FAU - Wang, Mengmeng
AU  - Wang M
AD  - Clinical Pharmacology Laboratory, The Second Affiliated Hospital, Soochow 
      University, Suzhou 215004, China.
FAU - Hu, Qingfang
AU  - Hu Q
AD  - Department of Endocrinology, The Second Affiliated Hospital, Soochow University, 
      Suzhou 215004, China.
FAU - Li, Sicheng
AU  - Li S
AD  - Department of Endocrinology, The Second Affiliated Hospital, Soochow University, 
      Suzhou 215004, China.
FAU - Wang, Meng
AU  - Wang M
AUID- ORCID: 0000-0001-6679-5166
AD  - Clinical Pharmacology Laboratory, The Second Affiliated Hospital, Soochow 
      University, Suzhou 215004, China.
FAU - Hu, Ji
AU  - Hu J
AUID- ORCID: 0000-0002-3443-999X
AD  - Department of Endocrinology, The Second Affiliated Hospital, Soochow University, 
      Suzhou 215004, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20191103
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - *DNA Methylation
MH  - Diabetes Mellitus, Type 2/blood/complications/diagnosis/*genetics
MH  - Diabetic Nephropathies/blood/diagnosis/*genetics
MH  - Diabetic Neuropathies/blood/diagnosis/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
PMC - PMC6875377
COIS- The authors declare no competing financial interests.
EDAT- 2019/11/30 06:00
MHDA- 2020/04/28 06:00
PMCR- 2019/11/03
CRDT- 2019/11/30 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/08/12 00:00 [accepted]
PHST- 2019/11/30 06:00 [entrez]
PHST- 2019/11/30 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2019/11/03 00:00 [pmc-release]
AID - 10.1155/2019/2494057 [doi]
PST - epublish
SO  - J Diabetes Res. 2019 Nov 3;2019:2494057. doi: 10.1155/2019/2494057. eCollection 
      2019.